|
|
肺动脉高压研究进展
|
Abstract:
肺动脉高压(PH)是以肺动脉系统循环阻力进行性增加为特征的一组疾病，其病理过程涉及肺血管的收缩和重构、肺血管平滑肌和内皮细胞的异常增生以及原位血栓形成等。这些病理变化导致肺动脉压力升高，加重右心室负荷，最终可能引发右心功能衰竭而死亡。近些年来随着诊疗水平的提升，以及人们就诊意愿的提高，肺动脉高压被越来越多的诊断。但对于其病因、治疗、管理及合并症等方面仍是难点，其次当患者确诊PH时已错过最佳治疗时期。因此提高对肺动脉高压的认识、正确的早期筛查及早期治疗十分重要。本文就肺动脉高压病因、治疗管理及合并症等研究的进展进行综述。
Pulmonary hypertension (PH) is a group of diseases characterized by progressive increase in circulatory resistance of the pulmonary artery system. The pathologic process involves contraction and remodeling of pulmonary blood vessels, abnormal proliferation of pulmonary smooth muscle and endothelial cells, and in-situ thrombosis. These pathological changes lead to increased pulmonary artery pressure and increased right ventricular load, which may eventually lead to right heart failure and death. In recent years, with the improvement of diagnosis and treatment level and the improvement of people’s willingness to seek medical treatment, pulmonary hypertension has been diagnosed more and more. However, the etiology, treatment, management and comorbidities are still difficult. Secondly, when patients are diagnosed with PH, the optimal treatment period has been missed. Therefore, it is very important to improve the understanding of pulmonary hypertension, correct early screening and early treatment. This article reviews the progress of the etiology, treatment, management and complications of pulmonary hypertension.
| [1] | 段永建, 易群. 肺动脉高压病因及治疗研究进展[J]. 西部医学, 2016, 28(8): 1178-1180+1185. |
| [2] | 杨杏, 叶瑞华, 周丽芹. 肺动脉高压患者的病因构成与肺动脉压力因素[J]. 华夏医学, 2020, 33(4): 67-70. https://doi.org/10.19296/j.cnki.1008-2409.2020-04-018 |
| [3] | 万钧, 翟振国. 肺动脉高压临床诊治和管理中需要关注的热点问题——基于《2022 ESC/ERS肺动脉高压诊治指南》与《中国肺动脉高压诊断与治疗指南(2021版)》的比较与解读[J]. 中国全科医学, 2023, 26(3): 255-261+267. |
| [4] | Mocumbi, A., Humbert, M., Saxena, A., Jing, Z., Sliwa, K., Thienemann, F., et al. (2024) Pulmonary Hypertension. Nature Reviews Disease Primers, 10, Article No. 1. https://doi.org/10.1038/s41572-023-00486-7 |
| [5] | Liu, S., Nambiar Veetil, N., Li, Q., Kucherenko, M.M., Knosalla, C. and Kuebler, W.M. (2022) Pulmonary Hypertension: Linking Inflammation and Pulmonary Arterial Stiffening. Frontiers in Immunology, 13, Article ID: 959209. https://doi.org/10.3389/fimmu.2022.959209 |
| [6] | Rabinovitch, M., Guignabert, C., Humbert, M. and Nicolls, M.R. (2014) Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circulation Research, 115, 165-175. https://doi.org/10.1161/circresaha.113.301141 |
| [7] | Evans, C.E., Cober, N.D., Dai, Z., Stewart, D.J. and Zhao, Y. (2021) Endothelial Cells in the Pathogenesis of Pulmonary Arterial Hypertension. European Respiratory Journal, 58, Article ID: 2003957. https://doi.org/10.1183/13993003.03957-2020 |
| [8] | Balistrieri, A., Makino, A. and Yuan, J.X. (2023) Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels, and Ca2+ Signaling. Physiological Reviews, 103, 1827-1897. https://doi.org/10.1152/physrev.00030.2021 |
| [9] | Hassoun, P.M. (2021) Pulmonary Arterial Hypertension. New England Journal of Medicine, 385, 2361-2376. https://doi.org/10.1056/nejmra2000348 |
| [10] | 任成山, 卞士柱, 胡明冬. 肺动脉高压的成因及治疗新理念[J]. 中华肺部疾病杂志(电子版), 2023, 16(1): 1-5. |
| [11] | 刘思言, 崔狄宇, 陈运清. 肺动脉高压相关病理机制的研究进展[J]. 现代医药卫生, 2024, 40(2): 288-292. |
| [12] | 樊芳芳, 施熠炜. 《中国肺动脉高压诊断与治疗指南(2021版)》解读: 肺动脉高压诊断流程[J]. 国际呼吸杂志, 2022, 42(5): 326-331. |
| [13] | Ruopp, N.F. and Cockrill, B.A. (2022) Diagnosis and Treatment of Pulmonary Arterial Hypertension. JAMA, 327, 1379-1391. https://doi.org/10.1001/jama.2022.4402 |
| [14] | Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., Brida, M., et al. (2022) 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Respiratory Journal, 61, Article ID: 2200879. https://doi.org/10.1183/13993003.00879-2022 |
| [15] | Hoeper, M.M., Pausch, C., Olsson, K.M., Huscher, D., Pittrow, D., Grünig, E., et al. (2021) COMPERA 2.0: A Refined Four-Stratum Risk Assessment Model for Pulmonary Arterial Hypertension. European Respiratory Journal, 60, Article ID: 2102311. https://doi.org/10.1183/13993003.02311-2021 |
| [16] | Andre, P., Joshi, S.R., Briscoe, S.D., Alexander, M.J., Li, G. and Kumar, R. (2022) Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling. Frontiers in Medicine, 8, Article ID: 814222. https://doi.org/10.3389/fmed.2021.814222 |
| [17] | Yung, L., Yang, P., Joshi, S., Augur, Z.M., Kim, S.S.J., Bocobo, G.A., et al. (2020) ACTRIIA-Fc Rebalances Activin/GDF versus BMP Signaling in Pulmonary Hypertension. Science Translational Medicine, 12, eaaz5660. https://doi.org/10.1126/scitranslmed.aaz5660 |
| [18] | Joshi, S.R., Liu, J., Bloom, T., Karaca Atabay, E., Kuo, T., Lee, M., et al. (2022) Sotatercept Analog Suppresses Inflammation to Reverse Experimental Pulmonary Arterial Hypertension. Scientific Reports, 12, Article No. 7803. https://doi.org/10.1038/s41598-022-11435-x |
| [19] | Hoeper, M.M., Badesch, D.B., Ghofrani, H.A., Gibbs, J.S.R., Gomberg-Maitland, M., McLaughlin, V.V., et al. (2023) Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 388, 1478-1490. https://doi.org/10.1056/nejmoa2213558 |
| [20] | Hennigs, J.K., Cao, A., Li, C.G., Shi, M., Mienert, J., Miyagawa, K., et al. (2021) PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension. Circulation Research, 128, 401-418. https://doi.org/10.1161/circresaha.119.316339 |
| [21] | Tang, L., Cai, Q., Wang, X., Li, X., Li, X., Chen, L., et al. (2023) Canagliflozin Ameliorates Hypobaric Hypoxia-Induced Pulmonary Arterial Hypertension by Inhibiting Pulmonary Arterial Smooth Muscle Cell Proliferation. Clinical and Experimental Hypertension, 45, Article ID: 2278205. https://doi.org/10.1080/10641963.2023.2278205 |
| [22] | He, Y., Zuo, C., Jia, D., Bai, P., Kong, D., Chen, D., et al. (2020) Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling. American Journal of Respiratory and Critical Care Medicine, 201, 1263-1276. https://doi.org/10.1164/rccm.201911-2137oc |
| [23] | Kurosawa, R., Satoh, K., Kikuchi, N., Kikuchi, H., Saigusa, D., Al-Mamun, M.E., et al. (2019) Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension. Circulation Research, 125, 309-327. https://doi.org/10.1161/circresaha.119.315229 |
| [24] | Sitbon, O., Bosch, J., Cottreel, E., Csonka, D., de Groote, P., Hoeper, M.M., et al. (2019) Macitentan for the Treatment of Portopulmonary Hypertension (PORTICO): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial. The Lancet Respiratory Medicine, 7, 594-604. https://doi.org/10.1016/s2213-2600(19)30091-8 |
| [25] | Grünig, E., Jansa, P., Fan, F., Hauser, J.A., Pannaux, M., Morganti, A., et al. (2024) Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 83, 473-484. https://doi.org/10.1016/j.jacc.2023.10.045 |
| [26] | Ciarka, A., Doan, V., Velez-Roa, S., Naeije, R. and van de Borne, P. (2010) Prognostic Significance of Sympathetic Nervous System Activation in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 181, 1269-1275. https://doi.org/10.1164/rccm.200912-1856oc |
| [27] | Velez-Roa, S., Ciarka, A., Najem, B., Vachiery, J., Naeije, R. and van de Borne, P. (2004) Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension. Circulation, 110, 1308-1312. https://doi.org/10.1161/01.cir.0000140724.90898.d3 |
| [28] | Maron, B.A. and Leopold, J.A. (2015) Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension. Circulation, 131, 2079-2091. https://doi.org/10.1161/circulationaha.114.006980 |
| [29] | Zhang, H., Wei, Y., Zhang, C., Yang, Z., Kan, J., Gu, H., et al. (2022) Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. JACC: Cardiovascular Interventions, 15, 2412-2423. https://doi.org/10.1016/j.jcin.2022.09.013 |
| [30] | 张璐, 卞士柱. 肺动脉高压患者药物治疗依从性及健康管理分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(1): 107-109. |
| [31] | 叶瑞华, 杨杏, 高洁, 等. 肺动脉高压的临床特点及呼吸道护理管理对患者预后的影响分析[J]. 现代诊断与治疗, 2020, 31(16): 2648-2649. |
